Effects of bazedoxifene/conjugated estrogens on quality of life in postmenopausal women with symptoms of vulvar/vaginal atrophy

Climacteric

Volumn 13, Issue 2, 2010, Pages 132-140

  Bachmann, G ^a   Bobula, J ^b   Mirkin, S ^b  

^a Department of Emergency Medicine   (United States)

^b PFIZER INC   (United States)

Author keywords

Bazedoxifene; Conjugated estrogens; Postmenopausal; Tissue selective estrogen complex; Tsec

Indexed keywords

BAZEDOXIFENE; CONJUGATED ESTROGEN; PLACEBO;

ADULT; ARTICLE; BOTHERSOMENESS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG WITHDRAWAL; EMOTIONAL DISORDER; ESTROGEN THERAPY; FEMALE; FUNCTIONAL ASSESSMENT; HOT FLUSH; HUMAN; HUMAN CELL; LIBIDO; LUBRICATION; MAJOR CLINICAL STUDY; MOOD DISORDER; MULTICENTER STUDY; ORGASM; PH; PHYSICAL CAPACITY; POSTMENOPAUSE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SEXUAL AROUSAL; SEXUAL FUNCTION; SEXUAL SATISFACTION; SLEEP DISORDER; SOCIAL STATUS; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; VAGINA ATROPHY; VAGINA SMEAR; VASOMOTOR REFLEX;

ADMINISTRATION, INTRAVAGINAL; ATROPHY; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; ESTROGENS, CONJUGATED (USP); FEMALE; HUMANS; INDOLES; MIDDLE AGED; POSTMENOPAUSE; QUALITY OF LIFE; SELECTIVE ESTROGEN RECEPTOR MODULATORS; SEXUAL BEHAVIOR; TREATMENT OUTCOME; VAGINA; VAGINAL DISEASES; VULVA;

EID: 77249172217     PISSN: 13697137     EISSN: 14730804     Source Type: Journal    
DOI: 10.3109/13697130903305627     Document Type: Article

References (36)

1. Bachmann GA, Nevadunsky NS. Diagnosis and treatment of atrophic vaginitis. Am Fam Physician 2000;61:3090-3096
2. Bachmann GA. Vasomotor flushes in menopausal women. Am J Obstet Gynecol 1999;180: S312-16
3. Feldman BM, Voda A, Gronseth E. The prevalence of hot flash and associated variables among perimenopausal women. Res Nurs Health 1985;8:261-268
4. Dennerstein L, Dudley EC, Hopper JL, Guthrie JR, Burger HG. A prospective population-based study of menopausal symptoms. Obstet Gynecol 2000;96:351-358
5. Utian WH. Psychosocial and socioeconomic burden of vasomotor symptoms in menopause: a comprehensive review. Health Qual Life Outcomes 2005;3:47
6. Pandit L, Ouslander JG. Postmenopausal vaginal atrophy and atrophic vaginitis. Am J Med Sci 1997;314:228-231
7. Cauley JA, Seeley DG, Ensrud K, Ettinger B, Black D, Cummings SR. Estrogen replacement therapy and fractures in older women. Study of Osteoporotic Fractures Research Group. Ann Intern Med 1995;122:9-16
8. Constantine GD, Pickar JH. Estrogens in postmenopausal women: recent insights. Curr Opin Pharmacol 2003;3:626-634
9. Gold DT, Silverman SL. Do estrogen or selective estrogen receptor modulators improve quality of life for women with postmenopausal osteoporosis? Curr Osteoporos Rep 2007;5:3-7
10. Pitkin J, Rees MC, Gray S, Lumsden MA, Stevenson J, Williamson J. Managing the menopause - British Menopause Society Council consensus statement on hormone replacement therapy. J Br Menopause Soc 2003;9: 129-131
11. North American Menopause Society. Role of progestogen in hormone therapy for postmenopausal women: position statement of The North American Menopause Society. Menopause 2003;10:113-132
12. Barnabei VM, Grady D, Stovall DW, et al. Menopausal symptoms in older women and the effects of treatment with hormone therapy. Obstet Gynecol 2002;100:1209-1218
13. Jenkins MR, Sikon AL. Update on nonhormonal approaches to menopausal management. Cleve Clin J Med 2008;75:S17-24
14. Kharode Y, Bodine PV, Miller CP, Lyttle CR, Komm BS. The pairing of a selective estrogen receptor modulator, bazedoxifene, with conjugated estrogens as a new paradigm for the treatment of menopausal symptoms and osteoporosis prevention. Endocrinology 2008;149: 6084-6091
15. Jordan VC, Gapstur S, Morrow M. Selective estrogen receptor modulation and reduction in risk of breast cancer, osteoporosis, and coronary heart disease. JNatlCancer Inst2001;93:1449-1457
16. Komm BS. A new approach to menopausal therapy: the tissue selective estrogen complex. Reprod Sci 2008;15:984-992
17. Miller PD, Chines AA, Christiansen C, et al. Effects of bazedoxifene on BMD and bone turnover in postmenopausal women: 2-yr results of a randomized, double-blind, placebo-, and active-controlled study. J Bone Miner Res 2008;23:525-535
18. Silverman SL, Christiansen C, Genant HK, et al. Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3- year, randomized, placebo- and active-controlled clinical trial. J Bone Miner Res 2008;23:1923-1934
19. Lindsay R, Gallagher JC, Kagan R, Pickar JH, Constantine G. Efficacy of tissue-selective estrogen complex of bazedoxifene/conjugated estrogens for osteoporosis prevention in at-risk postmenopausal women. Fertil Steril 2009;92:1045-1052
20. Lobo RA, Pinkerton JV, Gass ML, et al. Evaluation of bazedoxifene/ conjugated estrogens for the treatment of menopausal symptoms and effects on metabolic parameters and overall safety profile. Fertil Steril 2009;92: 1025-1038
21. Pinkerton JV, Utian WH, Constantine GD, Olivier S, Pickar JH. Relief of vasomotor symptoms with the tissue-selective estrogen complex containing bazedoxifene/conjugated estrogens: a randomized, controlled trial. Menopause 2009 Jun 10 [Epub ahead of print]
22. Pickar JH, Yeh IT, Bachmann G, Speroff L. Endometrial effects of a tissue selective estrogen complex containing bazedoxifene/conguated estrogens as a menopausal therapy. Fertil Steril 2009;92:1018-1024
23. Archer DF, Lewis V, Carr BR, Olivier S, Pickar JH. Bazedoxifene/ conjugated estrogens (BZA/CE): incidence of uterine bleeding in postmenopausal women. Fertil Steril 2009;92: 1039-1044
24. Kagan R, Williams RS, Pan K, Mirkin S, Pickar JH. A randomized, placebo- and active-controlled trial of bazedoxifene/conjugated estrogens (BZA/CE) for treatment of moderate to severe vulvar/vaginal atrophy in postmenopausal women. Menopause 2009; in press
25. McGahuey CA, Gelenberg AJ, Laukes CA, et al. The Arizona Sexual Experience Scale (ASEX): reliability and validity. J Sex Marital Ther 2000;26:25-40
26. Lewis JE, Hilditch JR, Wong CJ. Further psychometric property development of the Menopause- Specific Quality of Life questionnaire and development of a modified version, MENQOLIntervention questionnaire. Maturitas 2005;50: 209-221
27. Hilditch JR, Lewis J, Peter A, et al. A menopause- specific quality of life questionnaire: development and psychometric properties. Maturitas 1996;24:161-175
28. Hill CD, Fehnel SE, Bobula JD, Yu H, McLeod LD. Development and preliminary validation of the Menopause Symptoms Treatment Satisfaction Questionnaire (MS-TSQ). Menopause 2007;14:1047-1055
29. Utian W. The true clinical features of postmenopause and oop̈horectomy, and their response to oestrogen therapy. S Afr Med J 1972; 46:732-737
30. Utian WH. Quality of life (QOL) in menopause. Maturitas 2007;57:100-102
31. Ford K, Sowers M, Crutchfield M, Wilson A, Jannausch M. A longitudinal study of the predictors of prevalence and severity of symptoms commonly associated with menopause. Menopause 2005;12:308-317
32. Levine KB, Williams RE, Hartmann KE. Vulvovaginal atrophy is strongly associated with female sexual dysfunction among sexually active postmenopausal women. Menopause 2008;15: 661-666
33. Society of Obstetricians and Gynaecologists of Canada. SOGC clinical practice guidelines. The detection and management of vaginal atrophy. Number 145, May 2004. Int J Gynaecol Obstet 2005;88:222-228
34. North American Menopause Society. Estrogen and progestogen use in postmenopausal women: July 2008 position statement of The North American Menopause Society. Menopause 2008;15:584-602
35. Farquhar CM, Marjoribanks J, Lethaby A, Lamberts Q, Suckling JA. Long term hormone therapy for perimenopausal and postmenopausal women. Cochrane Database Syst Rev 2005;63: CD004143
36. Utian W, Yu H, Bobula J, Mirkin S, Olivier S, Pickar JH. Bazedoxifene/conjugated estrogens and quality of life in postmenopausal women. Maturitas 2009;63:329-335